Invention Grant
- Patent Title: Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
-
Application No.: US16807514Application Date: 2020-03-03
-
Publication No.: US11639386B2Publication Date: 2023-05-02
- Inventor: Leslie S. Johnson , Ezio Bonvini , Chia-Ying Kao Lam , Paul A. Moore , Liqin Liu , Scott Koenig
- Applicant: MacroGenics, Inc.
- Applicant Address: US MD Rockville
- Assignee: MacroGenics, Inc.
- Current Assignee: MacroGenics, Inc.
- Current Assignee Address: US MD Rockville
- Agency: Auerbach, LLC
- Agent Jeffrey I. Auerbach
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/46 ; C07K16/30 ; A61K39/395 ; A61K39/00
Abstract:
CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
Public/Granted literature
- US20200216537A1 Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof Public/Granted day:2020-07-09
Information query
